Anixa Biosciences (ANIX) News
NASDAQ: ANIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANIX news summary
We found 3 recent headlines mentioning Anixa Biosciences (ANIX): 1 in the past week and 2 in the past 30 days, most often from PR Newswire, Nasdaq. ANIX is making an outsized move today, down 6.15% at $2.44, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial", was published by PR Newswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Anixa Biosciences headlines
- Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical TrialCollaboration to support development of a stable, scalable formulation for clinical development and potential commercialization SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.…PR Newswire
- Friday 10/23 Insider Buying Report: NVA, ANIXAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On…NasdaqNVA, ANIX, LEN.B
- Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus ConferenceDr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")…PR Newswire